Reduction in ovarian androgens, potential reversal of polycystic ovary morphology with GLP-1 RA [56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84]. This evidence concerns the gene GCG and polycystic ovary syndrome.